New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new four-year follow-up results from the Phase 3 GLOW study (Abstract #93), which showed investigational, fixed-duration treatment with IMBRUVICA® + venetoclax (I+V) reduced the risk of progression or death by 79 percent among older and/or unfit patients with previously untreated chronic lymphocytic leukemia (CLL) compared to patients treated with chemoimmunotherapy.[i] These results were highlighted in an oral presentation during the 2022 American Society of Hematology (ASH) Annual Meeting.1CLL is the most com...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
What Happens When CEOs Get Sick?
When a CEO of a company falls ill, it doesn’t just affect one person—it affects a whole group of stakeholders. This played out recently when C.S. Venkatakrishnan, CEO of Barclays, announced he was diagnosed with Non-Hodgkin Lymphoma, according to a disclosure by the British universal bank to the…#nationalamusementsinc #oscarmunoz #nonhodgkinlymphoma #universityofvirginia #accenture #danish #singapore #redstone #universityofnotredame #singaporemanagementuniversity (Source: Reuters: Health)
Source: Reuters: Health - December 1, 2022 Category: Consumer Health News Source Type: news
For Camp Lejeune Victims Exposed to Toxic Water, a New Law Promises Compensation —and Closure
Many of Ann Johnson’s life milestones were marked at Camp Lejeune, a sprawling U.S. Marine Corps base camp on the North Carolina coast. She moved to the base in 1982, when her stepfather was stationed there. In 1983, she graduated from Camp Lejeune High School. In 1984, she got married and, at the age of 18, gave birth to her first child at the on-base hospital.
Johnson had a difficult pregnancy, gaining 120 pounds due to a complication that leads to excess amniotic fluid. In retrospect, she says, this was the first sign that something was wrong. Then, on the day her daughter, Jacquetta, was born, she didn’t cr...
Source: TIME: Health - November 16, 2022 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Source Type: news
Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs
Interim data from phase III HAVEN 7 study reinforceHemlibra ’s efficacy and safety in infants with severehaemophilia A without factor VIII inhibitors1New and updated data support use ofPolivy in diffuse large B-cell lymphoma, including its potential as a treatment option for previously untreated patients2New and updated data for innovative CD20xCD3 T-cell engaging bispecific antibodiesLunsumio andglofitamab further enhance their potential as effective, off-the-shelf, fixed-duration treatment options for people with lymphoma3,4,5,6,7First phase III data forcrovalimab show the co-primary efficacy endpoints were met, with s...
Source: Roche Media News - November 3, 2022 Category: Pharmaceuticals Source Type: news
Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs
Interim data from phase III HAVEN 7 study reinforceHemlibra ’s efficacy and safety in infants with severehaemophilia A without factor VIII inhibitors1New and updated data support use ofPolivy in diffuse large B-cell lymphoma, including its potential as a treatment option for previously untreated patients2New and updated data for innovative CD20xCD3 T-cell engaging bispecific antibodiesLunsumio andglofitamab further enhance their potential as effective, off-the-shelf, fixed-duration treatment options for people with lymphoma3,4,5,6,7First phase III data forcrovalimab show the co-primary efficacy endpoints were met, with s...
Source: Roche Investor Update - November 3, 2022 Category: Pharmaceuticals Source Type: news
Outcome and Factors of Lymphoma in Sjogren's Syndrome Outcome and Factors of Lymphoma in Sjogren's Syndrome
Primary Sjogren ' s syndrome is associated with an increased risk of non-Hodgkin ' s lymphoma. What do we know about the clinical features and survival of these patients?Rheumatology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - October 5, 2022 Category: Pathology Tags: Rheumatology Journal Article Source Type: news
Breast Implants May Be Linked to Additional Cancers, F.D.A. Warns
On rare occasions, new cancers have been found in women with both textured and smooth implants, filled with saline or silicone, federal health officials said. (Source: NYT Health)
Source: NYT Health - September 10, 2022 Category: Consumer Health News Authors: Roni Caryn Rabin Tags: your-feed-science Women and Girls Implants Plastic Surgery Non-Hodgkin ' s Lymphoma Breast Cancer Silicon Mastectomy Surgery and Surgeons Allergan Inc Food and Drug Administration United States Source Type: news
Jane Fonda's Non-Hodgkin Lymphoma
(MedPage Today) -- Academy-Award-winning actress Jane Fonda, 84, recently took to Instagram with some health news:
"So, my dear friends, I have something personal I want to share. I've been diagnosed with non-Hodgkin's lymphoma and have started... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 6, 2022 Category: Hematology Source Type: news
Jane Fonda Has Non - Hodgkin Lymphoma
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 6, 2022 Category: Cancer & Oncology Tags: Oncology, News, Source Type: news
Jane Fonda Has Non-Hodgkin Lymphoma
TUESDAY, Sept. 6, 2022– Actress Jane Fonda has announced she has non-Hodgkin lymphoma.
Fonda, 84, said she has started chemotherapy to fight the highly treatable cancer, calling herself very lucky because 80% of patients survive.
Also known... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 6, 2022 Category: General Medicine Source Type: news
Non-Hodgkin's lymphoma: What is the cancer that Jane Fonda announced she has?
Actress and activist Jane Fonda announced this week that she's been diagnosed with non-Hodgkin's lymphoma and has "started chemo treatments." But what is this form of cancer? Here are details. #janefonda #activist (Source: Reuters: Health)
Source: Reuters: Health - September 3, 2022 Category: Consumer Health News Source Type: news
Jane Fonda, actor and climate activist, diagnosed with non-Hodgkin's lymphoma
"This is a very treatable cancer. 80% of people survive, so I feel very lucky," she wrote on Instagram. #activist #janefonda (Source: Reuters: Health)
Source: Reuters: Health - September 2, 2022 Category: Consumer Health News Source Type: news
Jane Fonda announces she's been diagnosed with non-Hodgkin's Lymphoma
Jane Fonda has been diagnosed with non-Hodgkin's Lymphoma and has begun chemotherapy treatment, the legendary actress and activist said in post shared on her verified social media account. #activist #janefonda (Source: Reuters: Health)
Source: Reuters: Health - September 2, 2022 Category: Consumer Health News Source Type: news
Jane Fonda announces she's been diagnosed with non-Hodgkin lymphoma
The two-time Oscar winner says she's started chemotherapy, but won't let that treatment slow her activism. #janefonda (Source: Reuters: Health)
Source: Reuters: Health - September 2, 2022 Category: Consumer Health News Source Type: news
U.S. FDA Approves IMBRUVICA ® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease
August 24, 2022 (HORSHAM, PA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy. This milestone marks the first pediatric indication for IMBRUVICA® and the introduction of a new oral suspension formulation for patients ages one to less than 12. IMBRUVICA® is now the first FDA-approved therapy for these younger patients who previously had no approv...
Source: Johnson and Johnson - August 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
